Cytokinetics(US:CYTK) Prnewswire·2025-11-10 13:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cytokinetics, Incorporated regarding potential class action claims due to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to inflated stock prices and subsequent losses for investors [2][4]. Group 1: Allegations and Misleading Statements - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission timeline and approval process for aficamten, claiming expected FDA approval in the second half of 2025 based on a September 26, 2025 PDUFA date [2]. - It was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process, indicating a reckless decision to omit critical information [2]. Group 2: Impact on Shareholders - As a result of the misleading statements, class members purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth about the NDA submission was disclosed [2]. - The deadline for shareholders to register for the class action is November 17, 2025, and there is no cost or obligation to participate [3]. Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and seeking recovery for losses incurred due to deceitful practices by companies [4]. - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3].